Expect a sharp negative stock reaction on the open. Monitor for analyst downgrades and any updates on the BEACON study. The continued BEACON program provides a small offset, but the idiopathic PD market was the primary opportunity.
Price Chart
Executive Summary
Denali Therapeutics and Biogen announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints. Development of BIIB122 in idiopathic Parkinson's disease will be discontinued, while the Phase 2a BEACON study in LRRK2 variant carriers continues. This is a significant pipeline setback for Denali.
Key Facts
- Phase 2b LUMA study (n=648) did not meet primary endpoint of Time to Confirmed Worsening in MDS-UPDRS Part II and III combined score.
- Secondary endpoints also showed no benefit for BIIB122 versus placebo.
- Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease.
- Denali will continue the Phase 2a BEACON study in LRRK2 pathogenic variant carriers, with data expected in first half of 2027.
- Exploratory biomarkers showed >90% peripheral LRRK2 kinase inhibition and up to ~30% reduction in CSF pRab10.
Financial Impact
Significant devaluation of the Parkinson's disease pipeline; BIIB122 was a key partnered asset with Biogen. The discontinuation removes a major value driver for Denali.
Risk Factors
- The BEACON study may also fail, eliminating the entire LRRK2 program.
- Partnership with Biogen may be reevaluated, impacting future collaboration revenues.
- Potential need for additional capital if pipeline value erodes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299824 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $21.57 $20.06 | ▼ −7.00% | ▼ −6.34% | $20.00 (−7.28%) |
Sep 4, 2026 28d ago | Insider Cluster | $22.08 $20.38 | ▼ −7.70% | ▼ −6.58% | $20.00 (−9.42%) |
Aug 6, 2026 8w ago | 8-K | $24.83 $24.40 | ▼ −1.73% | ▼ −2.13% | $20.00 (−19.45%) |
Jul 27, 2026 9w ago | Press Release | $24.05 $23.15 | ▲ +3.74% | ▲ +6.01% | $20.00 (+16.84%) |
Jun 18, 2026 15w ago | 8-K | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 18, 2026 15w ago | Press Release | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.02 $23.49 | ▲ +11.75% | ▲ +11.32% | $20.00 (−4.85%) |
May 21, 2026 19w ago | Press Release | $18.64 $20.41 | ▼ −9.50% | ▼ −7.84% | $20.00 (−7.30%) |
May 7, 2026 21w ago | Press Release | $19.62 $19.39 | ▼ −1.17% | ▼ −2.64% | $20.00 (+1.94%) |
Apr 3, 2026 26w ago | 8-K | $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $20.00 (+3.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access